4D-150 gene therapy reduces treatment burden in wet AMD

MONTREAL — In a phase 2b study, an intravitreal gene therapy reduced the treatment burden in patients with neovascular age-related macular degeneration, according to a study.“4D-150 is an [adeno-associated virus] that has evolved to cross retinal barriers well, to have high gene expression and to minimize immune reaction,” Carl C. Awh, MD, FASRS, said in a presentation at the